Main content

    Esophageal / Gastric Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments
    Description: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with a histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction and who have previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: about Study Taiho 302

    • updated February 2016

    Back to top